Qual é o preço para Innate Pharma S.A. (IPH)

O preço para Innate Pharma S.A. (IPH) é $2.13

Qual é a capitalização de mercado para Innate Pharma S.A. (IPH)

A capitalização de mercado para Innate Pharma S.A. (IPH) é $200.27M

Innate Pharma S.A. (IPH) Preço e Capitalização de Mercado

Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.

Preço para IPH	Ativo B	Capitalização de mercado de B	Resultados
$57,764.65 $200.27M	NVDA	$5.424T	+2,708,413.32%
$50,859.62 $200.27M	AAPL	$4.776T	+2,384,644.92%
$43,148.78 $200.27M	GOOG	$4.052T	+2,023,093.00%
$39,306.80 $200.27M	MSFT	$3.691T	+1,842,947.23%
$29,224.14 $200.27M	AMZN	$2.744T	+1,370,183.82%

Preço para IPH

Ativo B

Capitalização de mercado de B

Resultados

$57,764.65 $200.27M